Objective: To compare the efficacy of using mild ovarian stimulation protocol and conventional stimulation protocol in IVF outcome. Design: Prospective randomized trial Setting: University IVF setting. Patient(s): The study compromised a total 200 subinfertile couple that women had regulary menstruation. Intervention(s): Patients were randomized to treatment clomiphene citrate, gonadotropin and GnRH antagonist (100 patients) or GnRH agonist and gonadotropin ( 100 patients). Main outcome measure: Clinical pregnancy rate. Key Words: clomiphene citrate, GnRH agonist, GnRH antagonist, in vitro fertilization, pregnancy rate.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
200
100 mg from cycle day 3 through 7
cycle day 8
Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).
75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)
Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (\<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.
150-225 IU recombinant FSH (r\_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
Yazd Research and Clinical Center For Infertility
Yazd, Yazd Province, Iran
clinical pregnancy rate
Time frame: 2 weeks
ovarian stimulation safety
Time frame: 3weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.